Russia’s largest plant for the production of vaccines and one of the biggest in Eastern Europe was recently commissioned in the Yaltunovo area of the Ryazan region by Fort Group, a leading Russian investment group.
The investment in the project amounted to 4.8 billion roubles ($150 million), the majority of which were provided by Vnesheconombank, one of Russia’s largest banks.
The new complex will have the capacity to produce up to 40 million doses of seasonal influenza vaccine, 120 million doses of pandemic influenza vaccine, 20 million doses of other viral vaccines, 100 million doses of recombinant proteins and up to 50 million of special forms of drugs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze